Detection of occult medullary thyroid cancer recurrence with 2-Deoxy-2-[F-18]fluoro-d-glucose-PET and PET/CT

Molecular Imaging and Biology

Volumn 9, Issue 2, 2007, Pages 72-77

  Iagaru, Andrei ^a   Masamed, Rinat ^b   Singer, Peter A ^b   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

FDG; Medullary thyroid cancer; PET CT

Indexed keywords

CALCITONIN; FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER LOCALIZATION; CANCER STAGING; CERVICAL LYMPH NODE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MEDIASTINUM METASTASIS; METASTASIS; OCCULT CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA;

ADOLESCENT; ADULT; BRAIN STEM NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33847411464     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-006-0072-1     Document Type: Article

References (21)

1. Jemal A, Siegel A, Ward E, Murray T, Xu J, Smigal C, et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106-130 (Mar-Apr)
2. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428 (Nov)
3. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS (1993) Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1057 (Dec)
4. O'Riordain DS, O'Brien T, Weaver AL, Gharib H, Hay ID, Grant CS, et al. (1994) Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116:1017-1023 (Dec)
5. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: Results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 48:265-273 (Mar)
6. Musholt TJ, Musholt PB, Dehdashti F, Moley JF (1997) Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: A clinical and molecular study. Surgery 122:1049-1060; discussion 1060-1061 (Dec)
7. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA (1999) Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9:797-804 (Aug)
8. Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST, Bading JR (1996) PET and [18F]-FDG in oncology: A clinical update. Nucl Med Biol 23:717-735 (Aug)
9. Gasparoni P, Rubello D, Ferlin G (1997) Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 20:527-530 (Oct)
10. Rufini V, Salvatori M, Garganese MC, Di Giuda D, Lodovica Maussier M, Troncone L (2000) Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 25:273-282 (Apr-Jun)
11. de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT (2004) Impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11:786-794 (Aug)
12. Adalet I, Kocak M, Oguz H, Alagol F, Cantez S (1999) Determination of medullary thyroid carcinoma metastases by 201Tl, 99Tcm(V)DMSA, 99Tcm-MIBI and 99Tcm-tetrofosmin. Nucl Med Common 20:353-359 (Apr)
13. Ugur O, Kostakglu L, Guler N, Caner B, Uysal U, Elahi N, et al. (1996) Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med 23:1367-1371 (Oct)
14. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A (2000) The value of F-18 FDG PET in patients with medullary thyroid cancer. Eur J Nucl Med 27:490-496 (May)
15. Crippa F, Alessi A, Gerali A, Bombardieri E (2003) FDG-PET in thyroid cancer. Tumori 89:540-543 (Sep-Oct)
16. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E (2001) 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64-71 (Jan)
17. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicentre study. Eur J Nucl Med 28:1671-1676 (Nov.)
18. Li S, Beheshti M (2005) The radionuclide molecular imaging and therapy of neuroendocrine tumors. Current Cancer Drug Targets 5:139-148 (Mar)
19. Gotthardt M, Battmann A, Hoffken H, Schurrat T, Pollum H, Beuter D, et al. (2004) 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: A clinical study and an analysis of the literature. Nucl Med Commun 25:439-443 (May)
20. Bockisch A, Brandt-Mainz K, Gorges R, Muller S, Stattaus J, Antoch G (2003) Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 30:22-25 (May)
21. Szakall S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. (2002) 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66-71 (Jan)